<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

News

Jump to a page: Press Releases Media Kit

Biodesix Secures Oncimmune

Biodesix announced its intent to acquire the Oncimmune Holdings Group’s laboratory and (IPN) malignancy test in the US

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Biodesix to acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

Immodulon Adopts AI Tool to Accelerate Pancreatic Cancer Clinical Trial

Immodulon will utilize biomarkers identified by Biodesix' machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.

Biodesix, Immodulon Team Up for Pancreatic Cancer Treatment

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex.

Multivariate Blood Test Can Predict Outcomes for Non-Small Cell Lung Cancer

Biodesix, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer.

Medical Device and Diagnostic Industry

A new collaboration could be key in the early detection of lung cancer.

Clinical Omics

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

Fierce Biotech

Biodesix Partners with MRM for mass spec proteomics development

Clinical Lab Products: Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

DDNews: VeriStrat Proves Its Prognostic Capabilities

Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late

1 2 3 4 5 6 Last